Overview

Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia

Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.
Phase:
Phase 1
Details
Lead Sponsor:
Ehab L Atallah
Medical College of Wisconsin
Treatments:
Azacitidine
Enzyme Inhibitors
Pevonedistat
Venetoclax